Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,056,197
  • Shares Outstanding, K 68,285
  • Annual Sales, $ 189,760 K
  • Annual Income, $ -196,540 K
  • EBIT $ -192 M
  • EBITDA $ -191 M
  • 60-Month Beta 2.14
  • Price/Sales 31.71
  • Price/Cash Flow N/A
  • Price/Book 42.28

Options Overview Details

View History
  • Implied Volatility 67.05% (-5.46%)
  • Historical Volatility 54.43%
  • IV Percentile 72%
  • IV Rank 39.73%
  • IV High 112.19% on 07/08/25
  • IV Low 37.30% on 05/16/25
  • Expected Move (DTE 25) 11.56 (13.03%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 947
  • Volume Avg (30-Day) 322
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 4,519
  • Open Int (30-Day) 4,062
  • Expected Range 77.13 to 100.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.84
  • Number of Estimates 6
  • High Estimate $-0.73
  • Low Estimate $-0.98
  • Prior Year $-0.81
  • Growth Rate Est. (year over year) -3.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.50 +17.50%
on 03/30/26
91.12 -3.93%
on 03/23/26
+0.09 (+0.10%)
since 03/20/26
3-Month
74.50 +17.50%
on 03/30/26
111.25 -21.31%
on 02/03/26
-15.05 (-14.67%)
since 01/20/26
52-Week
55.31 +58.27%
on 05/14/25
122.20 -28.36%
on 12/11/25
+25.80 (+41.79%)
since 04/17/25

Most Recent Stories

More News
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 87.54 (-1.30%)
Rhythm Pharmaceuticals Announces Changes to Board of Directors

-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical...

RYTM : 87.54 (-1.30%)
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical...

RYTM : 87.54 (-1.30%)
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

PITTSBURGH , March 20, 2026 /PRNewswire/ -- PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it...

RYTM : 87.54 (-1.30%)
Stocks Fall on Spillover Effects from Iran War

The S&P 500 Index ($SPX ) (SPY ) today is down -0.88%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.22%. March E-mini S&P futures...

GOOGL : 339.24 (-0.71%)
AMAT : 395.26 (-0.42%)
AAPL : 270.21 (-0.01%)
SNDK : 924.00 (+0.33%)
DHI : 148.50 (-0.87%)
BLDR : 89.99 (+1.68%)
$IUXX : 26,672.43 (+1.29%)
ASML : 1,446.77 (-0.89%)
FIGS : 16.13 (-0.25%)
ZNM26 : 111-195 (-0.10%)
MSFT : 420.35 (-0.58%)
KBH : 53.75 (-0.98%)
Stocks Decline as Bond Yields Climb on Inflation Fears

The S&P 500 Index ($SPX ) (SPY ) today is down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.64%. March E-mini S&P futures...

GOOGL : 339.24 (-0.71%)
AAPL : 270.21 (-0.01%)
INTU : 393.28 (+0.01%)
DDOG : 125.57 (-0.83%)
$IUXX : 26,672.43 (+1.29%)
FIGS : 16.13 (-0.25%)
ZNM26 : 111-195 (-0.10%)
MSFT : 420.35 (-0.58%)
TSLA : 398.40 (-0.55%)
ESM26 : 7,140.50 (-0.29%)
$DOWI : 49,447.43 (+1.79%)
SM : 26.50 (+2.04%)
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction...

RYTM : 87.54 (-1.30%)
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

-- Four substudies did not meet pre-specified primary endpoints --  -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozygous...

RYTM : 87.54 (-1.30%)
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- - 18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity --...

RYTM : 87.54 (-1.30%)
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE ®  (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic...

RYTM : 87.54 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 94.51
2nd Resistance Point 92.51
1st Resistance Point 90.60
Last Price 87.54
1st Support Level 86.69
2nd Support Level 84.69
3rd Support Level 82.78

See More

52-Week High 122.20
Fibonacci 61.8% 96.65
Fibonacci 50% 88.75
Last Price 87.54
Fibonacci 38.2% 80.86
52-Week Low 55.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.